Having trouble accessing articles? Reset your cache.

Astellas lays groundwork for oncolytic virus combination therapy

How Astellas is using cytokine expression to improve oncolytic virus antitumor T cell immunity

With its next-gen oncolytic virus, Astellas is reinforcing the promise of improved efficacy for versions that make cytokines stimulating T cells as well as innate immune cells.

After more than two decades in development with limited clinical efficacy, oncolytic viruses have returned to the spotlight; since 2016, at least nine pharmas have acquired

Read the full 529 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE